GenFleet Therapeutics
http://www.genfleet.com/en
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From GenFleet Therapeutics
Deal Watch: Jazz Breaks Into Immuno-Oncology Via Licensing Pact With Werewolf
AstraZeneca licenses bispecific cancer antibody candidate from Harbour Biomed. Regeneron seeks new approach to gene therapy delivery in deal with ViGeneron.
Oncology Developer Yahong Bags China’s First Biotech IPO Of 2022
Jiangsu Yahong and 11 Chinese biotechs raised a combined $1.1bn via public listings and VC/PE deals in the run-up to and first week of the new year.
2021 Marked New Era Of Domestic Collaboration in China
Major deals showed an increasing focus on domestic tie-ups while an unsatiable appetite for innovation drove drug firms to actively seek out biotechs for collaboration.
Asia Deal Watch: Beximco Broadens Offerings, Capabilities With Sanofi Bangladesh Buy
Plus deals involving Biosplice/Haisco, SciClone/Tarveda, Everest/Sinovent/SinoMab, Kyowa Kirin/AM-Pharma, Sandoz/Bio-Thera, Dr. Reddy’s/Citius, Jiangsu Hengrui/Mabworks, GeneQuantum/BrightGene, Innovent/GenFleet and Takeda/Mirum.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals